We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus (SAGE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02539459
Recruitment Status : Terminated (Extreme toxicity, met toxicity stopping rules)
First Posted : September 3, 2015
Results First Posted : February 17, 2021
Last Update Posted : December 15, 2022
Sponsor:
Collaborator:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Fox Chase Cancer Center

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this research study is to see if oral everolimus is tolerable and effective in the treatment of sporadic Angiomyolipomas (AMLs). AMLs are the most common non-cancerous tumor of the kidney. They are composed of blood vessels, muscle cells and fat cells.Everolimus is already an approved drug for several other diseases like kidney cancer, but is being studied now specifically to see if it is helpful for people with AML.

Condition or disease Intervention/treatment Phase
Sporadic Angiomyolipomas (AMLs) Drug: Everolimus Phase 2

Detailed Description:

Primary Objective

1. To evaluate the efficacy and tolerability of everolimus in reducing tumor volume in sporadic AMLs as measured by dynamic contrast enhanced magnetic resonance imaging (DCE MRI), in patients who might otherwise be considered for active surgical or percutaneous intervention.

Secondary Objectives

  1. To evaluate health-related quality of life (HRQoL) in subjects treated with everolimus for sporadic AMLs.
  2. To assess the growth kinetics of sporadic AMLs in patients who have been treated with everolimus as part of the study and demonstrate an objective response as well as those who have been treated with everolimus during the study with a suboptimal or no response.
  3. To measure the rate of surgical or percutaneous (embolization) intervention at 1 year from day 1 of study.
  4. To assess the safety and tolerability of everolimus in patients with sporadic AML.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus Therapy
Actual Study Start Date : September 23, 2015
Actual Primary Completion Date : August 20, 2018
Actual Study Completion Date : August 20, 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Everolimus

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Treatment (everolimus)
Patients will take 10 mg (1 tablet) of everolimus each day for 4 months
 Drug: Everolimus
10 mg tablets


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Number of Patients With Tumor Volume Reduction Greater Than 25% [ Time Frame: 12 months ]
    Measuring the efficacy and tolerability of everolimus by measuring the number of patients with tumor volume reduction greater than 25% in sporadic AMLs as measured by DCE MRI


Secondary Outcome Measures :
  1. Safety and Tolerability of Everolimus in Patients With Sporadic AML [ Time Frame: 12 months ]
    Number of participants with treatment-related adverse events requiring dose reduction or study withdrawal as assessed by Common Toxicity Criteria for Adverse Effects (CTCAE v4.0)


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Must have a diagnosis of renal AML > 3 cm confirmed on pre-enrollment Dynamic Contrast Enhanced MRI (DCE-MRI)
  • Must not have received any prior treatment for AML
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
  • Absolute neutrophil count >= 1,500/ microliter (mcL)
  • Hemoglobin >=10 g/dL
  • Platelets >= 100,000/ mcL
  • international normalized ratio (INR) <= 1.2 X Upper limit Normal (ULN)
  • activated partial thromboplastin time (aPTT) <= 1.2 X ULN
  • aspartate aminotransferase (AST) / alanine transaminase (ALT) <= 2.5 X ULN
  • Total bilirubin <= 2.0mg/dL
  • Renal Function epidermal growth factor receptor (eGFR) >= 30 mL/min via calculated creatinine clearance
  • Fasting serum cholesterol <= 300 mg/dL OR <= 7.75 mmol/L AND fasting triglycerides <= 2.5x ULN.

Exclusion Criteria:

  • History of tuberous sclerosis, LAM or any active malignancy
  • Treatment with any other investigational agents for any other disease
  • Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding or affect absorption of investigational product
  • Active diarrhea of any grade.
  • History of human immunodeficiency virus (HIV) infection, hepatitis B or C (screening for all three is mandatory prior to study); prior hepatitis C infection
  • Presence of any active or ongoing infection.
  • Any known uncontrolled underlying pulmonary disease by history, physical exam or if applicable pulmonary function test (PFTs)
  • History of certain cardiovascular conditions within the past 6 months
  • History of Class III or IV congestive heart failure, as defined by the New York Heart Association Classification of Congestive Heart Failure.
  • History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months.
  • Corrected QT interval (QTc) > 480 milliseconds
  • Poorly controlled hypertension, defined as systolic blood pressure (SBP) of >= 140 millimeters of mercury(mmHg) or diastolic blood pressure (DBP) of >= 90 mmHg.
  • Evidence of active bleeding or bleeding diathesis
  • Uncontrolled diabetes mellitus (defined by a Hgb A1c >8) obtained within 14 days prior to registration. Optimal glucose control (Hgb A1c <= 8) must be achieved before registration and monitored during protocol treatment
  • Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures.
  • Unable or unwilling to discontinue use of prohibited medications
  • Concurrent therapy given to treat cancer including treatment with an investigational agent or concurrent participation in another clinical trial involving anti-cancer investigational drug.
  • Administration of any investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of study treatment.
  • Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to everolimus
  • Prior or current use of systemic anti-vascular endothelial growth factor (VEGF) inhibitors, cytokines or mechanistic target of rapamycin (mTOR) inhibitors (e.g. interferon, interleukin 2).
  • Pregnant or nursing (lactating) women
  • Women of child-bearing potential (WOCBP) must use highly effective methods of contraception during the study and 8 weeks after.
  • Unable to obtain a contrast (gadolinium) based DCE MRI, including include patients with pacemakers, automatic implantable cardioverter/defibrillator (AICDs), non MRI compatible metallic implants or eGFR <30.
  • Must not have received immunization with an attenuated live vaccine within seven days prior to registration nor have plans to receive such vaccination while on protocol treatment
  • Must not be taking, nor plan to take while on protocol treatment, strong cytochrome P450 3A4 (CYP3A4) inhibitors, (e.g. ketoconazole, itraconazole, voriconazole, posaconazole, fluvoxamine, nefazodone, nelfinavir, ritonavir) and/or strong CYP3A4 inducers (e.g. phenytoin, rifampin, rifabutin) within 14 days prior to randomization.
  • History of another primary malignancy, with the exceptions of: non-melanoma skin cancer, and carcinoma in situ of the cervix, uteri, or breast from which the patient has been disease free for >= 3 years
  • Childs-Pugh A-C liver disease (Appendix II)
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02539459


Locations
Layout table for location information
United States, Connecticut
Yale School of Medicine
New Haven, Connecticut, United States
United States, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts, United States
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States
United States, New York
Memorial Sloan Kettering
New York, New York, United States
United States, North Carolina
Duke University Health System
Durham, North Carolina, United States
United States, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111
University of Pennsylvania
Philadelphia, Pennsylvania, United States
United States, Texas
M D Anderson Cancer Center
Houston, Texas, United States
Sponsors and Collaborators
Fox Chase Cancer Center
Novartis Pharmaceuticals
Investigators
Layout table for investigator information
Principal Investigator: Robert G Uzzo, MD PI
  Study Documents (Full-Text)

Documents provided by Fox Chase Cancer Center:
Study Protocol and Statistical Analysis Plan  [PDF] March 28, 2017

More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications of Results:

Layout table for additonal information
Responsible Party: Fox Chase Cancer Center
ClinicalTrials.gov Identifier: NCT02539459    
Other Study ID Numbers: GU-070
First Posted: September 3, 2015    Key Record Dates
Results First Posted: February 17, 2021
Last Update Posted: December 15, 2022
Last Verified: December 2022
Additional relevant MeSH terms:
Layout table for MeSH terms
Angiomyolipoma
Neoplasms, Adipose Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Perivascular Epithelioid Cell Neoplasms
 Everolimus
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs